Jilly F. Evans

16.0k total citations · 4 hit papers
105 papers, 9.9k citations indexed

About

Jilly F. Evans is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Jilly F. Evans has authored 105 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Physiology, 32 papers in Molecular Biology and 30 papers in Pharmacology. Recurrent topics in Jilly F. Evans's work include Asthma and respiratory diseases (49 papers), Inflammatory mediators and NSAID effects (25 papers) and Estrogen and related hormone effects (15 papers). Jilly F. Evans is often cited by papers focused on Asthma and respiratory diseases (49 papers), Inflammatory mediators and NSAID effects (25 papers) and Estrogen and related hormone effects (15 papers). Jilly F. Evans collaborates with scholars based in United States, Canada and Japan. Jilly F. Evans's co-authors include Stacia Kargman, Philip J. Vickers, Masanobu Oshima, Makoto M. Taketo, Elizabeth Kwong, Bruno C. Hancock, Joseph Dinchuk, Hiroko Oshima, James M. Trzăskos and Joseph A. Mancini and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Jilly F. Evans

105 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

1996 2.0k citations Stacia Kargman, Jilly F. Evans et al. profile →
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

1995 723 citations Stacia Kargman, Gary P. O’Neill et al. PubMed profile →
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1990 622 citations Philip J. Vickers, Jilly F. Evans et al. profile →
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2012 606 citations Jilly F. Evans et al. profile →

Peers

Countries citing papers authored by Jilly F. Evans

Since Specialization

Citations

This map shows the geographic impact of Jilly F. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jilly F. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jilly F. Evans more than expected).

Fields of papers citing papers by Jilly F. Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jilly F. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jilly F. Evans. The network helps show where Jilly F. Evans may publish in the future.

Co-authorship network of co-authors of Jilly F. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Jilly F. Evans. A scholar is included among the top collaborators of Jilly F. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jilly F. Evans. Jilly F. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis 2024 ·American Journal of Respiratory Cell and Molecular Biology ·Jilly F. Evans, (unknown), Yan Tang, (unknown), Alexander R. Mukhitov, (unknown), Susan M. Lin, (unknown), Maria C. Basil, Edward Cantu, Elizabeth P. Henske, Vera P. Krymskaya	1
2	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database 2019 ·IUPHAR/BPS Guide to Pharmacology CITE ·Magnus Bäck, Charles Brink, Nan Chiang, Sven‐Erik Dahlén, Gordon Dent, Jeffrey M. Drazen, Jilly F. Evans, Douglas W.P. Hay, Motonao Nakamura, William S. Powell, Joshua Rokach, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu, Takehiko Yokomizo	1
3	Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells 2018 ·PLoS ONE ·Blanca E. Himes, (unknown), Lurong Lian, Maya Shumyatcher, (unknown), Elena N. Atochina‐Vasserman, (unknown), Marisa S. Bartolomei, Jilly F. Evans, Vera P. Krymskaya	5
4	5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor 2011 ·Journal of Medicinal Chemistry ·Nicholas Stock, Gretchen Bain, (unknown), Yiwei Li, (unknown), Jeffrey Roppe, Angelina M. Santini, Janice Darlington, Pat Prodanovich, Christopher D. King, Christopher Baccei, Catherine Lee, Haojing Rong, Charles W. Chapman, (unknown), (unknown), Lucia Correa, John H. Hutchinson, Jilly F. Evans, Peppi Prasit	39
5	DP2 Receptor Antagonists: Novel Therapeutic Target for COPD 2010 ·Karin J. Stebbins, Jilly F. Evans, Daniel S. Lorrain	4
6	Effects of Prolactin on TSC2 -Null Eker Rat Cells and in Pulmonary Lymphangioleiomyomatosis 2010 ·American Journal of Respiratory and Critical Care Medicine ·Yasuhiro Terasaki, Kinnosuke Yahiro, Gustavo Pacheco–Rodriguez, Wendy K. Steagall, Mario Stylianou, Jilly F. Evans, Ameae M. Walker, Joel Moss	13
7	Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D2 receptor antagonist 2010 ·Bioorganic & Medicinal Chemistry Letters ·Nicholas Stock, Deborah L. Volkots, Karin J. Stebbins, (unknown), Brian A. Stearns, Jeffrey Roppe, Tim Parr, Christopher Baccei, Gretchen Bain, Charles W. Chapman, Lucia Correa, Janice Darlington, Christopher D. King, Catherine Lee, Daniel S. Lorrain, Pat Prodanovich, Angelina M. Santini, Jilly F. Evans, John H. Hutchinson, Peppi Prasit	9
8	Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Daniel S. Lorrain, Gretchen Bain, Lucia Correa, Charles W. Chapman, (unknown), Angelina M. Santini, Pat Prodanovich, Janice Darlington, John H. Hutchinson, Christopher D. King, Catherine Lee, Christopher Baccei, Yiwei Li, (unknown), Jilly F. Evans	11
9	Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis 2009 ·Bioorganic & Medicinal Chemistry Letters ·Brian A. Stearns, Christopher Baccei, Gretchen Bain, (unknown), (unknown), Heather Coate, Jilly F. Evans, Patrick Fagan, John H. Hutchinson, Christopher D. King, Catherine Lee, Daniel S. Lorrain, Peppi Prasit, Pat Prodanovich, Angelina M. Santini, (unknown), Nicholas Stock, (unknown)	37
10	The nuclear membrane organization of leukotriene synthesis 2008 ·Proceedings of the National Academy of Sciences ·Asim K. Mandal, P. Jones, Angela M. Bair, Peter Christmas, Douglas K. Miller, (unknown), Douglas Wisniewski, John G. Menke, Jilly F. Evans, Bradley T. Hyman, Brian J. Bacskai, Mei Chen, David Lee, Boris Nikolic, Roy J. Soberman	82
11	International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors 2003 ·Pharmacological Reviews ·Charles Brink, Sven‐Erik Dahlén, Jeffrey M. Drazen, Jilly F. Evans, Douglas W.P. Hay, S. Nicosia, Charles N. Serhan, Takao Shimizu, Takehiko Yokomizo	228
12	A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha 2003 ·Pharmacogenetics ·Miles D. Thompson, (unknown), Helen Galczenski, Kathy Siminovitch, Noé Zamel, Arthur S. Slutsky, Jeffrey M. Drazen, Susan R. George, W. McIntyre Burnham, Jilly F. Evans, Brian F. O’Dowd	42
13	Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes 2001 ·American Journal of Respiratory and Critical Care Medicine ·David J. Figueroa, Richard Breyer, (unknown), Stacia Kargman, Bruce L. Daugherty, K E Waldburger, Qingyun Liu, Michelle K. Clements, (unknown), Gary P. O’Neill, Thomas R. Jones, Kevin R. Lynch, Christopher P. Austin, Jilly F. Evans	225
14	Discovery and mapping of ten novel G protein-coupled receptor genes 2001 ·Gene ·Dennis K. Lee, Tuan Nguyen, Kevin R. Lynch, Regina Cheng, William B. Vanti, (unknown), (unknown), Jilly F. Evans, Susan R. George, Brian F. O’Dowd	170
15	Identification and Characterization of Novel Mammalian Neuropeptide FF-like Peptides That Attenuate Morphine-induced Antinociception 2001 ·Journal of Biological Chemistry ·Qingyun Liu, Xiao Ming Guan, William J. Martin, Terrence P. McDonald, Michelle K. Clements, Qingping Jiang, Zhizhen Zeng, Marlene A. Jacobson, David L. Williams, Hong Yu, (unknown), David J. Figueroa, John Mallee, Ruiping Wang, Jilly F. Evans, Robert J. Gould, Christopher P. Austin	233
16	Inflammatory Effector Mechanisms in Asthma 1995 ·American Journal of Respiratory and Critical Care Medicine ·Jeffrey M. Drazen, Jilly F. Evans, Richard L Stevens, M A Shipp	6
17	5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. 1993 ·The Journal of Experimental Medicine ·John Woods, Jilly F. Evans, Diane Ethier, S Scott, Philip J. Vickers, (unknown), Jeffrey A. Heibein, S. Charleson, Irwin Singer	341
18	5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. 1992 ·Molecular Pharmacology ·Joseph A. Mancini, Petpiboon Prasit, Marc G. Coppolino, (unknown), Serge Léger, Jilly F. Evans, John W. Gillard, Philip J. Vickers	31
19	Bestatin inhibits covalent coupling of [³H]LTA₄ to human leukocyte LTA₄hydrolase 1992 ·FEBS Letters ·Jilly F. Evans, Stacia Kargman	23
20	Studies of leukotriene antagonists and synthesis inhibitors in man. 1988 ·PubMed ·Neil Barnes, Jilly F. Evans, (unknown), Piper Pj, J Costello	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact